Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Keisuke Yamamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6323-9540; OpenAlex author ID A5009636601. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 6 papers · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 5 papers · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 26

  1. Hepatocytes promote liver metastasis of pancreatic cancer by providing serine. First author DOI 10.1038/s41586-026-11051-z↗
  2. Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis. Co-author DOI 10.1126/sciadv.adz8681↗
  3. WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway. Co-author DOI 10.1007/s00535-024-02192-x↗
  4. Targeting autophagy as a therapeutic strategy against pancreatic cancer. Co-author DOI 10.1007/s00535-022-01889-1↗
  5. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Co-author DOI 10.3390/cancers14184351↗
  6. Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2020.10.018↗
  7. Autophagy is required for proper cysteine homeostasis in pancreatic cancer through regulation of SLC7A11. Co-author DOI 10.1073/pnas.2021475118↗
  8. Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2020.10.016↗
  9. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Co-author DOI 10.1038/s41586-020-2229-5↗
  10. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
  11. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. Co-author DOI 10.1080/15548627.2020.1769973↗
  12. Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0959↗
  13. Quantitation of circulating satellite RNAs in pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.86646↗
  14. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  15. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  16. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  17. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  18. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Co-author DOI 10.1093/carcin/bgu136↗
  19. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  20. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  21. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  22. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  23. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  24. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Co-author DOI 10.1158/0008-5472.can-12-1453↗
  25. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Co-author DOI 10.1111/j.1349-7006.2012.02311.x↗
  26. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Co-author DOI 10.1159/000328767↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alec C. Kimmelman · 8 shared papers, 2020–2026 · strength 1.17
  2. Douglas E. Biancur · 6 shared papers, 2020–2026 · strength 0.92
  3. Yousuke Nakai · 16 shared papers, 2011–2022 · strength 0.86
  4. Mitsuhiro Fujishiro · 4 shared papers, 2022–2026 · strength 0.84
  5. Koji Miyabayashi · 14 shared papers, 2012–2025 · strength 0.70
  6. Hideaki Ijichi · 14 shared papers, 2012–2025 · strength 0.70
  7. Robert Singhung Banh · 5 shared papers, 2020–2026 · strength 0.68
  8. Elaine Y. Lin · 3 shared papers, 2020–2026 · strength 0.56
  9. Kazuhiko Koike · 15 shared papers, 2011–2020 · strength 0.55
  10. Hiroyuki Isayama · 14 shared papers, 2011–2020 · strength 0.49
  11. Richard Possemato · 2 shared papers, 2026 · strength 0.47
  12. Joseph Douglas Mancias · 4 shared papers, 2020–2021 · strength 0.42
  13. Hiroyuki Kato · 2 shared papers, 2022 · strength 0.37
  14. Ryota Takahashi · 3 shared papers, 2016–2025 · strength 0.37
  15. Andrew J. Aguirre · 2 shared papers, 2021–2026 · strength 0.36
  16. Dai Mohri · 9 shared papers, 2013–2020 · strength 0.34
  17. Takahiro Kishikawa · 3 shared papers, 2015–2025 · strength 0.33
  18. Motoyuki Otsuka · 3 shared papers, 2014–2025 · strength 0.33
  19. Dafna Bar‐Sagi · 2 shared papers, 2020–2026 · strength 0.32
  20. Joel Encarnación-Rosado · 2 shared papers, 2020–2026 · strength 0.32
  21. Joao A Paulo · 3 shared papers, 2020–2021 · strength 0.32
  22. Minoru Tada · 10 shared papers, 2011–2015 · strength 0.29
  23. Suguru Mizuno · 10 shared papers, 2011–2015 · strength 0.29
  24. Hirofumi Kogure · 10 shared papers, 2011–2015 · strength 0.29
  25. Takashi Sasaki · 10 shared papers, 2011–2015 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.